sponsored
PatientsVille.com Logo

PatientsVille

Monurol Medical Research Studies

Up-to-date List of Monurol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Monurol Medical Research Studies

Rank Status Study
1 Recruiting Single Dose Monurol for Treatment of Acute Cystitis
Condition: Urinary Tract Infection
Interventions: Drug: Fosfomycin;   Drug: TMP/SMX DS
Outcome Measures: To assess the efficacy of a single dose fosfomycin;   To assess the tolerance of a single does of fosfomycin
2 Not yet recruiting Fosfomycin Versus Meropenem in Bacteriemic Infections Caused by ESBL-E. Coli
Condition: Infection Due to ESBL Escherichia Coli
Interventions: Drug: Fosfomycin sodium intravenous;   Drug: Meropenem intravenous
Outcome Measures: Clinical and microbiological cure rate;   Early clinical response;   Mortality;   Length of hospital stay;   Safety of intravenous fosfomycin in this indication;   Recurrences (relapse and reinfection) rate;   Fosfomycin steady-state plasma concentration;   Microbiota impact of study treatment bacilli;   Emergence of resistant clinical isolates of Escherichia coli to fosfomycin and meropenem;   Early microbiological response;   Safety of intravenous antibiotic administration in this indication
3 Not yet recruiting Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women
Conditions: Urinary Tract Infections;   Cystitis
Interventions: Drug: nitrofurantoin;   Drug: fosfomycin
Outcome Measures: Number of participants with clinical cure, clinical failure, or indeterminate clinical response (see description below);   Number of participants with bacteriologic cure and with bacteriologic recurrence
4 Recruiting Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin fosfomycin inhalation solution;   Drug: Aerosolized placebo
Outcome Measures: Change from baseline in Clinical Pulmonary Infection Score (CPIS) during the planned 10-day treatment period.;   Composite endpoint of mortality and ventilator-free days;   Number of days free of mechanical ventilation from Day 1 through Day 28;   Number of ICU days from Day 1 through Day 28;   Microbiological response rates in patients positive for multi-drug resistant Gram-negative bacteria;   Mortality from Day 1 through Day 28;   Clinical relapse rate
5 Unknown  Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii
Condition: Drug Safety
Interventions: Drug: colistin;   Drug: colistin plus fosfomycin
Outcome Measures: number of subjects with cure or improvement;   number of subjects with eradication of causative bacteria
6 Recruiting Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
Condition: Urinary Tract Infections
Interventions: Drug: Fosfomycin 3 g;   Drug: Ciprofloxacin 500 mg
Outcome Measures: Bacteriuria;   Urinary Tract Infection;   Sepsis;   Pathogens present in urine and antimicrobial resistance;   Bacteremia;   Hematuria;   Hemospermia;   Rectal bleeding;   Urinary retention;   Difficulty for miction;   Genitourinary infections associated to fever (>38ºC);   Number of participants with adverse events
7 Recruiting Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
Condition: Staph Aureus Methicillin Resistant Bacteremia
Interventions: Drug: Fosfomycin 2gr/6h iv;   Drug: Daptomycin 10mg/kg/24h iv
Outcome Measures: Therapy response;   Mortality;   Severe adverse effects;   Number of persistent bacteremia;   Bacteremia recurrence
8 Recruiting Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
Condition: Infective Endocarditis
Interventions: Drug: Fosfomycin and imipenem;   Drug: Vancomycin
Outcome Measures: Proportion of patients with negative blood cultures.;   Toxicity due to treatment
9 Recruiting Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
Conditions: Urinary Tract Infection;   Asymptomatic Bacteriuria;   Allograft Rejection;   Microbiologic Resistance;   Hospitalization
Interventions: Drug: Fosfomycin-Trometamol;   Drug: Sulfamethoxazole trimethoprim
Outcome Measures: Urinary tract infection incidence in the first six months after kidney transplantation;   Complications related to the intervention, including rate of microbiological resistance.
10 Recruiting Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI
Condition: Urinary Tract Infection
Interventions: Drug: Ibuprofen;   Drug: Fosfomycin-Trometamol
Outcome Measures: number of additional treatments with antibiotics combined with number of symptoms;   number of defined daily doses of antibiotics;   number of SAEs;   number of relapses;   number of patients without symptoms;   symptom load (AUC);   symptom load;   symptoms load with regard to specific symptoms;   activity impairment assessment
11 Unknown  Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection
Condition: Bacterial Infection
Intervention:
Outcome Measure:
12 Recruiting Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.
Condition: Urinary Tract Infections
Interventions: Drug: Diclofenac;   Drug: Norfloxacin
Outcome Measures: The proportion of patients with resolution of symptoms on day 4;   The proportion of patients ever on antibiotics between randomization and day 30 of follow-up;   The proportion of patients using single dose fosfomycin on day 4;   The proportion of patients with re-consultations because of UTI within 30 days;   The mean composite symptom scores on days 4, 7 and 30;   The proportion of patients with resolution of symptoms on day 7;   The proportion of patients with complete resolution of symptoms on days 4 and 7;   The time until resolution of symptoms;   The proportion of patients with adverse events;   Mean overall patient stratification;   Health-related quality of life on day 4;   Number of working days lost
13 Not yet recruiting Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E
Condition: Cancer
Interventions: Drug: ESBL eradication regimen;   Drug: Placebo ESBL eradication
Outcome Measures: Short-term intestinal eradication;   Long-term intestinal eradication d28;   Long-term intestinal eradication d42;   Short-term non-intestinal eradication;   Long-term non-intestinal eradication d28;   Long-term non-intestinal eradication d42;   Emerging presence of non-ESBL multi-drug resistant bacteria;   Intestinal microbiome;   Quantitative assessment of intestinal ESBL-E burden;   Incidence and severity of AEs;   Rate of AE-related study drug discontinuations
14 Not yet recruiting Patients Response to Early Switch To Oral:Osteomyelitis Study
Condition: Osteomyelitis
Interventions: Drug: oral antibiotics;   Procedure: intravenous antibiotics
Outcome Measures: Clinical Failures;   Evaluation of adverse events related to the use of antibiotics;   Cost of care from the hospital perspective
15 Recruiting Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study
Condition: Clinically Significant Bacteremia
Intervention:
Outcome Measures: Cure rate at day 14;   Mortality at 72 hours;   Mortality at 7 days;   Mortality at 14 days;   Mortality at 30 days;   Clinical Improvement at 72 hours;   Clinical cure at 28 days
16 Unknown  Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder
Conditions: Neurogenic Bladder;   Urinary Tract Infection
Intervention: Drug: Weekly Oral Cyclic Antibiotic programme
Outcome Measures: Number of symptomatic UTIs;   The number of feverish UTIs;   The number of hospitalizations;   The duration of UTI-related hospitalizations;   The tolerance level to the Weekly Oral Cyclic Antibiotic Programme, measured by any adverse effects to antibiotics;   The global antibiotic consumption.;   The number of urine culture negative;   The emergence of multi-resistant bacteria in urine (cultures), digestive bacteria (anal swabs), oro-pharynx bacteria (nasal swabs), and semi-quantitative research of multi-resistant bacteria in the stool.;   the quality of life
17 Unknown  Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Condition: Malaria
Intervention: Drug: Fosmidomycin and clindamycin
Outcome Measures: Cure rate;   cure rate

These studies may lead to new treatments and are adding insight into Monurol etiology and treatment.

A major focus of Monurol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Monurol